Effect of oral hormone replacement therapy on plasma homocysteine levels

Acta Obstetricia et Gynecologica Scandinavica

Volumn 85, Issue 11, 2006, Pages 1304-1306

  Guimarães, Daniela Amorim Melgaço ^a   Cardoso, Jarbas ^a   Dusse, Luci Maria Sant'Ana ^a   Franco, Romerson Martins ^b   Franco, Hilton De A ^b   Alvim, Túlio César ^b   Teixeira, George Da Silva ^b   Carvalho, Maria Das Graças ^a   Fernandes, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Maternidade Otaviano Neves   (Brazil)

Author keywords

C677T; Homocysteine; Hormone replacement therapy; MTHFR; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; GENE; GENE MUTATION; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; MTHFR GENE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; ADULT; CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION;

EID: 33750174341     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340600676136     Document Type: Article

References (16)

1. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, Den Heijer M, Kluijtmans LA, Van Den Heuvel LP, Rozen R. A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Gen. 1995;10:111-3.
2. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395-403.
3. Fujimura H, Kawasaki T, Sakata T. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res. 2000;98: 1-8.
4. Hak AE, Polderman KH, Westendrop IC, Jakobs C, Hofman A, Witterman JC, Stehouwer CD. Increased plasma homocysteine after menopause. Atherosclerosis. 2000;149:163.
5. Madsen JS, Kristensen SR, Klitgaard NA, Bladbjerg EM, Abrahamsen B, Stilgren L, Jespersen J. Effect of longterm hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am J Obstet Gynecol. 2002;187:33-9.
6. Mijatovic V, van der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med. 2001;39:764-7.
7. Chiantera V, Sarti CD, Fornaro F, Farzati A, Franciscis P, Sepe E, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause. 2003;10:286-91.
8. Van Baal WM, Smolders RGV, Van Der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine. Obstet Gynecol. 1999;94:485-91.
9. Hak AE, Bak AA, Lindemans J, Planellas J, Coelingh Bennink HJ, Hofman A, Grobbee DE, Witteman JC. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis. 2001;158:437.
10. Evio S, Tiitinen A, Turpeinen U, Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril. 2000;74:1081-3.
11. Bruschi F, Dal Pino D, Fiore V, Parazzini F, Di Pace R, Casena BM, Melotti D, Crosignani PG. Effect of oral or transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial. Maturitas. 2004;48: 33-8.
12. Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Cheystowski K, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism. 2005; 54:72-8.
13. D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet Gynecol Scand. 2005;84:474-7.
14. Arruda VR, Siqueira LH, Gonçalves MS, Von Zuben PM, Soares MC, Menezes R, Annichino-Bizzacchi JM, Costa FF. Prevalence of mutation C677T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998;78:332-5.
15. Women's Health Initiative. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002; 288:321-33.
16. Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J. 2004;148:34.